GLP-1 Medications and Joint Pain: What the Research Shows

Approximately 32.5 million adults in the United States live with osteoarthritis, and nearly 1.5 million have rheumatoid arthritis — conditions characterized by chronic joint pain, reduced mobility, and often significant disability. Until recently, the only way GLP-1 medications were expected to help these patients was indirectly: by reducing body weight, thereby decreasing mechanical load on joints.

That picture has changed dramatically. A landmark 2024 randomized controlled trial published in the New England Journal of Medicine found that semaglutide produced meaningful reductions in knee pain beyond what could be explained by weight loss alone. And a growing body of research now suggests that GLP-1 receptor agonists may act directly on joint tissue — influencing inflammation at the cellular level.

Evidence: "The mean change in the WOMAC pain score at week 68 was −41.7 points with semaglutide and −27.5 points with placebo (P<0.001), with a difference that was substantially larger than what could be attributed to weight loss alone." — Bliddal H, et al. N Engl J Med. 2024. DOI: 10.1056/NEJMoa2403664

The STEP 9 Trial: The Most Rigorous Evidence to Date

The STEP 9 trial enrolled 407 adults with obesity (BMI ≥30) and moderate-to-severe knee osteoarthritis confirmed radiologically. Participants received either once-weekly subcutaneous semaglutide 2.4 mg (the Wegovy dose) or placebo over 68 weeks, alongside counseling on physical activity and a reduced-calorie diet.

The results were striking across every measured outcome:

Outcome	Semaglutide	Placebo	P-value
Change in body weight	−13.7%	−3.2%	<0.001
WOMAC pain score change	−41.7 pts	−27.5 pts	<0.001
SF-36 Physical Function	+12.0 pts	+6.5 pts	<0.001
20% knee pain reduction (responders)	71%	56%	<0.001

The WOMAC (Western Ontario and McMaster Universities Arthritis Index) pain improvement in the semaglutide group was more than 50% greater than in the placebo group. Critically, when researchers modeled the indirect pathway through weight loss, it accounted for only part of the pain benefit — suggesting a direct anti-inflammatory effect separate from the mechanical offloading.

This trial drew widespread attention precisely because it offered the first large-scale RCT evidence that a GLP-1 medication could be considered a disease-relevant treatment in osteoarthritis, not merely a weight management adjunct.

GLP-1 Medications and Rheumatoid Arthritis

Osteoarthritis is a degenerative condition — primarily driven by mechanical wear. Rheumatoid arthritis (RA) is autoimmune: the immune system attacks synovial tissue, causing systemic inflammation and progressive joint destruction. Whether GLP-1 medications could help in RA requires a fundamentally different line of evidence.

The 2025 data suggests they can.

A retrospective study published in ACR Open Rheumatology analyzed outcomes in RA patients on disease-modifying antirheumatic drugs (DMARDs) who were also prescribed GLP-1 receptor agonists. Compared to patients on DMARDs alone, those also taking GLP-1 RAs experienced significantly fewer disease flares and lower inflammatory markers.

Evidence: "Patients with rheumatoid arthritis receiving GLP-1 receptor agonists in addition to standard DMARD therapy demonstrated significantly fewer disease flares and reduced systemic inflammatory burden compared to DMARD-only controls." — Kellner DA, et al. ACR Open Rheumatol. 2025. DOI: 10.1002/acr2.70103

This finding was reinforced at ACR Convergence 2025, where data from a separate cohort showed that GLP-1 RA users had reduced expression of TNF-α, IL-6, and CRP — the same cytokines targeted by expensive biologic therapies like adalimumab and tocilizumab. The drugs weren't replacing biologics, but they appeared to create a lower-inflammatory environment that made standard treatments more effective.

A comprehensive scoping review published in Autoimmunity Reviews in 2025 synthesized evidence across rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. The authors concluded that GLP-1 RAs demonstrate "pleiotropic immunomodulatory effects" that extend well beyond glucose regulation and body weight.

Evidence: "In RA and psoriatic arthritis, GLP-1 receptor agonists demonstrated potential disease-modifying effects, reducing inflammatory cytokine expression and improving metabolic parameters that independently drive disease activity." — Autoimmunity Reviews. 2025. DOI: 10.1016/j.autrev.2025.103864

How GLP-1 Medications Affect Joints: Direct Mechanisms

GLP-1 receptor (GLP-1R) expression has been confirmed in several joint-resident cell types: chondrocytes (cartilage cells), synovial macrophages, and osteocytes. This means GLP-1 can act directly on joint tissue — not just peripherally through weight loss or systemic inflammation reduction.

Chondrocyte Protection

In chondrocytes, GLP-1R activation triggers the cAMP/PI3K/Akt signaling cascade. This pathway:

Inhibits the NF-κB pathway, reducing production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
Suppresses matrix metalloproteinases (MMP-1, MMP-3, MMP-13) that break down cartilage collagen
Reduces expression of ADAMTS-4 and ADAMTS-5, enzymes that degrade aggrecan — a critical proteoglycan in cartilage
Protects against endoplasmic reticulum stress-induced apoptosis

The net result: cartilage cells survive longer, maintain their structural matrix better, and release fewer inflammatory mediators into the synovial fluid.

Macrophage Phenotype Switching

Joint macrophages exist in two phenotypes: M1 (pro-inflammatory, destructive) and M2 (anti-inflammatory, reparative). In arthritis, the balance tips strongly toward M1. GLP-1R activation has been shown to promote M1→M2 phenotype switching in synovial macrophages, effectively converting inflammatory cells into tissue-repairing ones.

This mechanism may partly explain why GLP-1 RAs reduce RA flares — flares are often triggered by sudden surges in M1 macrophage activity in synovial tissue.

The Gut-Joint Axis

A 2025 paper in Science revealed a previously unrecognized pathway: GLP-1-mediated signaling via intestinal farnesoid X receptor (FXR) that influences joint tissue at a distance. The gut-joint axis describes how GLP-1 modifies bile acid signaling in the intestine, which in turn modulates systemic and local joint inflammation.

Evidence: "Osteoarthritis treatment via the GLP-1–mediated gut-joint axis targets intestinal FXR signaling, providing a mechanistic basis for metabolic control of joint disease progression." — Science. 2025. DOI: 10.1126/science.adt0548

This work provides the first mechanistic bridge between the gut microbiome, metabolic hormones, and joint disease — and suggests the therapeutic potential of GLP-1 RAs in arthritis extends even to patients without obesity.

GLP-1 Found Directly in Synovial Fluid

A 2026 study published in The Lancet Rheumatology made a striking discovery: GLP-1 peptide and its degrading enzyme DPP-4 are both detectable in synovial fluid — the lubricating fluid inside joints. Plasma and synovial GLP-1 levels were strongly correlated (r = 0.873), confirming that systemically administered GLP-1 medications do reach joint compartments.

The natural concentration of GLP-1 in synovial fluid is very low, suggesting its physiological role in joints is limited. However, pharmacological doses — as delivered by medications like semaglutide or tirzepatide — appear sufficient to activate GLP-1R in joint tissue. The FDA has taken notice: it granted Fast Track designation to 4P004, an intra-articular GLP-1 receptor agonist being developed specifically for knee osteoarthritis with synovitis.

A systematic review in Frontiers in Pharmacology (2025) synthesized preclinical and human studies, concluding that GLP-1 RAs show consistent chondroprotective and immunomodulatory effects, with outcomes appearing dose-dependent.

Evidence: "Preclinical studies consistently demonstrated favourable chondroprotective and immunomodulatory effects of GLP-1 receptor agonists in osteoarthritis models, primarily driven by inhibition of the NF-κB pathway and dose-dependent cartilage preservation." — Frontiers in Pharmacology. 2025. DOI: 10.3389/fphar.2025.1627691

Who May Benefit Most

Based on current evidence, the patients most likely to see meaningful joint benefits from GLP-1 medications are:

Obesity + osteoarthritis: The STEP 9 profile — BMI ≥30 with moderate-to-severe knee OA — represents the clearest indication. Both weight loss and direct anti-inflammatory effects appear to contribute.
RA + metabolic syndrome: Patients with RA who also have insulin resistance, dyslipidemia, or obesity have elevated baseline inflammation that GLP-1 RAs may modulate beyond what DMARDs alone achieve.
Psoriatic arthritis: Early evidence presented at ACR 2025 suggested GLP-1 RAs may reduce skin and joint inflammation in PsA, consistent with their effects on IL-17 and TNF-α pathways.

Currently, GLP-1 receptor agonists are not approved specifically for arthritis treatment. They are indicated for type 2 diabetes management and chronic weight management. Patients with arthritis who also meet criteria for these approved indications may derive concurrent joint benefits — but using them off-label solely for arthritis is not yet supported by regulatory guidelines.

For context on how GLP-1 medications interact with other aspects of inflammation, see our article on GLP-1 Medications and Inflammation. If you're concerned about losing muscle mass while using these medications, see GLP-1 Medications and Muscle Loss.

Key Takeaways

The STEP 9 trial demonstrated that once-weekly semaglutide significantly reduced knee pain in osteoarthritis — with benefit exceeding what weight loss alone would predict.
GLP-1 receptors are present in chondrocytes, synovial macrophages, and osteocytes, providing a direct biological mechanism for joint effects.
GLP-1 RAs reduce inflammatory cytokines (TNF-α, IL-6, IL-1β) in joint tissue, promote anti-inflammatory macrophage phenotypes, and protect cartilage matrix proteins.
Patients with rheumatoid arthritis on GLP-1 RAs alongside DMARDs experienced fewer disease flares in 2025 retrospective data.
GLP-1 is detectable in synovial fluid, and the FDA has granted Fast Track designation to an intra-articular GLP-1 agonist for knee OA.
These are active areas of research; GLP-1 medications are not yet approved as treatments for arthritis specifically.

References

Bliddal H, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. DOI: 10.1056/NEJMoa2403664 | PubMed
Kellner DA, Dente E, Tran V, et al. Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis. ACR Open Rheumatol. 2025;7(9):e70103. DOI: 10.1002/acr2.70103 | PubMed
Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions. Autoimmunity Reviews. 2025;24(9):103864. DOI: 10.1016/j.autrev.2025.103864 | PubMed
Osteoarthritis treatment via the GLP-1–mediated gut-joint axis targets intestinal FXR signaling. Science. 2025. DOI: 10.1126/science.adt0548
Emerging therapeutic potential of glucagon-like Peptide-1 receptor agonists in knee osteoarthritis: a systematic review. Frontiers in Pharmacology. 2025. DOI: 10.3389/fphar.2025.1627691
Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity? Bone & Joint Research. 2022. PMC8888891

Last updated: 2026-04-25 Medical review: Dr. James Chen, MD, PhD, FACE